All In Biotech

Free tool

FAERS Monitor: Ingrezza Sprinkle

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218390 or its brand name (Ingrezza Sprinkle, Valbenazine Tosylate). Reports on generic versions are filed under their own applications.

Reports

426

Serious

367

86% of reports

Hospitalization

142

Death reported

56

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • tardive dyskinesia90
  • off label use31
  • somnolence31
  • completed suicide20
  • depression19
  • parkinsonism16
  • dyskinesia15
  • fall15
  • suicidal ideation14
  • anxiety13
  • malaise13
  • drug ineffective12
  • dysphagia12
  • hospitalisation12
  • tremor11

Reports by year received

View as table
YearReports
20172
20188
20198
202021
202118
202274
2023103
2024100
202555
202637

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,733 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
tardive dyskinesiaSignal90158.0131.513,859
parkinsonismSignal1681.250.21,186
dyskinesiaSignal1518.211.1228
completed suicideSignal2011.97.7189
somnolenceSignal317.65.4173
suicidal ideationSignal147.64.573
dysphagiaSignal126.23.648
depressionSignal194.12.742
hospitalisationSignal123.92.223
tremorSignal113.31.815
anxietySignal132.31.38
fallSignal152.21.49
off label use311.71.210
malaise131.50.92
drug ineffective120.40.38

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.